About: Cellanyx is developing proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and inform clinical decision making. The Company’s initial tests, for prostate cancer and Stage 0 breast cancer, both of which have demonstrated clinical proof of concept, are being developed to augment traditional pathology tests. Technology: Cellanyx’s technology analyzes multiple molecular, cellular and biophysical phenotypic markers of individual living cells and their behavior including protein dynamics and cell motility. The approach is enabled by a proprietary breakthrough technique for rapidly culturing primary tumor cells, coupled with microfluidics, microscopy, and advanced machine vision and machine learning artificial intelligence technologies. Prostate Cancer Phenotypic Biomarker Test: Cellanyx’s most advanced application is for enhanced risk stratification to predict adverse pathology at the time of radical prostatectomy in men with low and intermediate risk prostate cancer (pathologically classified based on their Gleason scores). The Company has demonstrated proof of concept in more than 300 prostate samples from radical prostatectomy patients, validating the test’s potential to identify adverse pathology characteristic of local aggressiveness and metastasis in patients with low and intermediate Gleason scores.